Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
Status:
Recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This trial tests if the combination of comprehensive metastasis directed therapy delivered by
a precision form of external beam radiotherapy (stereotactic ablative radiotherapy), combined
with PSMA targeted radiopharmaceutical therapy and cessation of castration, and then followed
by testosterone replacement, is an effective treatment for metastatic castration resistant
prostate cancer.
All patients will be treated with stereotactic ablative radiotherapy and PSMA targeted
radiopharmaceutical therapy with cessation of castration. Half of patients are randomized to
either receive, or not receive, subsequent testosterone replacement.